SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

• ClinicalTrials.gov Identifier: NCT01086254
• Recruitment Status: Completed
• First Posted: March 15, 2010
• Last Update Posted: September 24, 2013
• Sponsor: Sanofi
• Information provided by (Responsible Party): Sanofi

Tracking Information

• First Submitted Date: March 11, 2010
• First Posted Date: March 15, 2010
• Last Update Posted Date: September 24, 2013
• Study Start Date: May 2010
• Actual Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: March 12, 2010): overall response rate (ORR) that is defined in the RECIST 1.1 version, as: complete response rate + partial response rate [ Time Frame: up to a maximum follow-up of 25 weeks ]
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: March 12, 2010)

• progression free survival [ Time Frame: up to a maximum of 2 years ]
• overall survival [ Time Frame: up to a maximum of 2 years ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
• Official Title: Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer

Brief Summary

Primary Objective:

• to assess the objective response rate (ORR) of Iniparib (SAR240550) administered as a 60-min intravenous infusion twice weekly, when combined to gemcitabine/cisplatin chemotherapy regimen (GCS) as well as with the standard regimen of gemcitabine/cisplatin (GC) in patients with stage IV non small cell lung cancer.

Secondary objectives are:

• to assess the safety profiles of the study combination GCS and of the standard regimen GC;
• to assess the progression free survival and the overall survival in both arms;
• to assess the relationship between DNA repair pathway characteristics of tumors at baseline and clinical outcome of disease.
• to assess the effect of Iniparib on PAR level in peripheral blood mononuclear cells (PBMC). (As of 10 September 2010, the collection of PBMC is temporarily discontinued.)

Detailed Description

The duration of the study for a patient will include a period for inclusion of up to 3 weeks. The patients may continue treatment up to a maximum of 6 cycles or until disease progression, unacceptable toxicity or consent withdrawal, followed by a minimum of 30-day follow-up after the last study treatment administration.

Patients will be followed for at least 30 days after the last administration of study treatment for safety purpose. In case of study treatment discontinuation without disease progression, efficacy data will be collected every 6 weeks until disease progression, death or end of study whatever comes first. After disease progression, the patient will be followed-up every 12 weeks (3 months) for overall survival (OS) until death or end of study whatever comes first.

The end of the study will be one year after the first dose of the last treated patient.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Non-small Cell Lung Cancer Stage IV

Intervention

• Drug: Iniparib

  Pharmaceutical form: solution for infusion

  Route of administration: 60-minute IV infusion

  Other Names:

  • SAR240550
  • BSI-201
• Drug: gemcitabine

  Pharmaceutical form: solution for infusion

  Route of administration: 30-minute IV infusion

• Drug: cisplatin

  Pharmaceutical form: solution for infusion

  Route of administration: 1- to 4-hour IV infusion, according to the local standard

Study Arms

• Experimental: Iniparib/ Gemcitabine/ Cisplatin

  Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.

  Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.

  Interventions:

  • Drug: Iniparib
  • Drug: gemcitabine
  • Drug: cisplatin
• Active Comparator: Gemcitabine/ Cisplatin
  Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
  Interventions:

  • Drug: gemcitabine
  • Drug: cisplatin

• Publications *: Novello S, Besse B, Felip E, Barlesi F, Mazieres J, Zalcman G, von Pawel J, Reck M, Cappuzzo F, Ferry D, Carcereny E, Santoro A, Garcia-Ribas I, Scagliotti G, Soria JC. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Ann Oncol. 2014 Nov;25(11):2156-2162. doi: 10.1093/annonc/mdu384. Epub 2014 Aug 19.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 2, 2012): 119
• Original Estimated Enrollment (submitted: March 12, 2010): 105
• Actual Study Completion Date: December 2011
• Actual Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion criteria:

• Stage IV disease (including stage IIIB with pleural effusion) with no prior systemic therapy. Adjuvant therapy is allowed if ended more than 1 year before inclusion in the study.
• Histologically confirmed squamous cell bronchogenic carcinoma OR non squamous cell carcinoma.
• Patients with previous radiotherapy as definitive therapy for locally advanced non-small cell lung cancer are eligible, as long as the selected measurable lesions are outside the original radiation therapy port. Radiation therapy must have been completed >4 weeks prior to study entry.
• Palliative radiotherapy must have been completed > 2 weeks prior to study entry. Irradiated lesions may not serve as measurable lesions.
• At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Adequate bone marrow reserve.
• Adequate liver and renal function.
• Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment.

Exclusion criteria:

• Prior treatment with gemcitabine, platinum salts or any PARP inhibitor class compound.
• Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of the cervix, or other cancers cured by local therapy alone and with an expected disease-free survival of > or = 5 years.
• Major medical conditions that might affect study participation e.g. cardiac disease, uncontrolled infection (>Grade 2).
• Presence of active brain metastases.
• A major surgical procedure, open biopsy, or significant traumatic injury within 28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study.
• Any history of medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results
• Grade 2 or higher ear and labyrinth disorders.
• Known or suspected allergy/hypersensitivity to any agent given in the course of this trial.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: France, Germany, Italy, Spain, United Kingdom

Administrative Information

• NCT Number: NCT01086254
• Other Study ID Numbers: TCD11420; 2009-017270-21 ( EudraCT Number ); U1111-1116-5404 ( Other Identifier: UTN )
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Sanofi
• Study Sponsor: Sanofi
• Collaborators: Not Provided

Investigators

• Study Director: Clinical Sciences & Operations; Sanofi

• PRS Account: Sanofi
• Verification Date: September 2013